ArticleScientific reports2026
Network pharmacology analysis and cellular experiment validation of puerarin in attenuating TBI through suppression of ferroptosis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTBI is a neurological disorder closely associated with ferroptosis. Although puerarin has demonstrated neuroprotective effects, the mechanisms underlying its therapeutic action on TBI via ferroptosis regulation remain unclear.
objectiveThis study aimed to elucidate the potential mechanisms by which puerarin exerts therapeutic effects on TBI, focusing on ferroptosis, through an integrative approach combining network pharmacology, MD simulations, and in vitro experiments.
methodsPotential targets of puerarin were predicted using TCMSP, PharmMapper, and SwissTargetPrediction, while ferroptosis- and TBI-related genes were retrieved from FerrDb, OMIM and GeneCards. Differential expression analysis of TBI-related genes was performed using the GSE58483 dataset from the GEO database. GO/KEGG analysis were conducted using the Metascape platform. Molecular docking was carried out with AutoDock Vina and PyMol, followed by MD simulation using Gromacs 2022.6. In vitro experiments were conducted to further validate pathways and targets.
resultsKey targets, including AKT1, ALB, IL6, and NFKB1, were identified and found to be primarily involved in inflammation-related signaling pathways such as TNF and IL-17. Molecular docking demonstrated stable interactions between puerarin and these targets, which were further supported by MD simulations showing good structural stability and low interaction energies. In HT22 cells subjected to glutamate/erastin-induced ferroptosis, puerarin effectively counteracted ferroptotic cell damage.
conclusionThe present investigation reveals that puerarin may inhibit ferroptosis by regulating the TNF signaling pathway, thereby alleviating TBI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.